Kirstin Thelen
Wuppertal, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers.
Journal: Clinical and translational science
Published: January 10, 2024
A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis.
Journal: Kidney international
Published: October 20, 2023
Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease.
Journal: CPT: pharmacometrics & systems pharmacology
Published: March 31, 2022
Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions.
Journal: CPT: pharmacometrics & systems pharmacology
Published: April 01, 2021
Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential.
Journal: Journal of clinical pharmacology
Published: February 27, 2020
Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation.
Journal: Journal of thrombosis and haemostasis : JTH
Published: December 24, 2019
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
Journal: The Lancet. Haematology
Published: June 21, 2019
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
Journal: The Lancet. Haematology
Published: March 22, 2019
BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics.
Journal: Research and practice in thrombosis and haemostasis
Published: November 07, 2018
Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study.
Journal: Thrombosis journal
Published: October 05, 2018
Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study.
Journal: Thrombosis journal
Published: September 06, 2018
Last Updated: 09/26/2026